Indeed, the first FDA approval for a CDK inhibitor was not until 2015, when the selective CDK4/6i palbociclib entered clinical practice as treatment for hormone receptor (HR)-positive breast cancer (3). This evidence concerns the gene CDK4 and breast carcinoma.